Prothena Corp. plc (PRTA), a late-stage clinical biotechnology company, is on the verge of a potentially transformative year ahead, as it prepares for key data readouts over the next 12 months.
The company has a diverse pipeline of novel investigational therapies derived from its Protein Dysregulation Platform, which have the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. It has wholly owned programs as well as programs being developed in collaborations with Roche, Bristol Myers Squibb, and Novo Nordisk.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.